Applications of 4-[4-(Tert-Butoxycarbonyl)Piperazino]Benzoic Acid in Industrial Manufacturing

As a specialized manufacturer of pharmaceutical intermediates, we supply 4-[4-(Tert-Butoxycarbonyl)Piperazino]Benzoic Acid for use in advanced synthesis routes where stringent regulatory, formulation, and process requirements must be met. Below are established industrial scenarios where our product supports critical downstream production across regulated sectors.

1. Active Pharmaceutical Ingredient (API) Synthesis – Piperazine-Derived Antineoplastic Agents

This material enters the multi-step synthesis pathways for piperazine-substituted benzoic acid intermediates required in the production of targeted antineoplastic APIs. It serves as a protected structural unit, providing both piperazine functionalization and controlled deprotection during later-stage synthesis, supporting high purity and batch-level consistency for oncology pharmaceutical processes. Downstream manufacturers leverage its reactivity and stability as a core building block under tightly controlled cGMP conditions.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• United States Pharmacopeia (USP) General Chapters & Monographs (as applicable to downstream APIs)
• European Pharmacopoeia (Ph. Eur.) for relevant API intermediate control
• US FDA 21 CFR Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals

Typical usage ratio

• Used at stoichiometric quantities in the range of 0.95–1.10 molar equivalents relative to the target benzoic acid intermediate. Exact ratios depend on route yield optimization and impurity profile management.

Downstream process integration

• Functionalized as a protected amine/piperazine scaffold during early-to-mid-stage synthesis; subsequent Tert-Butoxycarbonyl (Boc) removal occurs during penultimate or final purification steps in dedicated reactor trains.

Final product types

• Small-molecule chemotherapeutic drugs (piperazine-based anti-cancer drugs)
• Piperazine-derivative API master batches
• Intermediates for kinase inhibitors and other targeted therapies
• Tablet- and injectable-grade drug substances after downstream purification

2. Custom Peptide Modification in Pharmaceutical Contract Manufacturing

In custom peptide synthesis, this benzoic acid derivative introduces a selectively Boc-protected piperazine moiety for terminal modification or side-chain linkage. Its incorporation is essential in projects where controlled reactivity and peptide chain protection are critical, such as in enhanced pharmacokinetic property peptides. It is widely adopted in CDMO and CMO facilities specializing in small-scale, high-value peptide drugs for investigational or commercial use, enabling clean deprotection under mild conditions that safeguard peptide integrity.

Industry compliance standards

• Good Manufacturing Practice (GMP, ICH Q7/EMA guidelines)
• ICH Q11: Development and Manufacture of Drug Substances
• USP <1045>: Biotechnology-Derived Articles
• Qualified Person (QP) release per EU GMP guidelines for batch release and traceability

Typical usage ratio

• Employed at 0.9–1.2 eq in relation to the peptide carboxylic or amine sites, typically calculated per coupling cycle and adjusted based on peptide hydrophobicity and resin loading.

Downstream process integration

• Coupled to peptide chains during solid-phase peptide synthesis (SPPS) sequences; Boc group cleavage performed post-assembly or prior to final purification using mild acids to minimize peptide degradation risk.

Final product types

• Therapeutic peptides and peptide-drug conjugates (PDCs)
• Research-grade modified peptides for preclinical studies
• Peptidic prodrugs and stabilized peptides
• Diagnostic peptide kits for in vitro and in vivo use

3. Chemical Intermediate for CNS-Active Pharmaceutical Development

Manufacturers of central nervous system (CNS) therapeutics utilize this piperazino-benzoic acid building block in the assembly of novel analogs targeting neuroreceptor modulation. It acts as an intermediate where Boc-protected piperazine substitution enables late-stage introduction of key pharmacophores before analytical validation. Its value lies in facilitating the introduction of substituted piperazine cycles in psychoactive and antidepressant drug scaffolds, with robust impurity tracking aligning with regulatory requirements for CNS drug preclinical and clinical trial supply chains.

Industry compliance standards

• ICH M7(R1): Assessment and Control of DNA Reactive (Mutagenic) Impurities
• EDQM Certificate of Suitability (CEP) system for CNS intermediates (Europe)
• GMP guidelines (FDA/EMA/PMDA)
• ISO 9001:2015 for chemical process management

Typical usage ratio

• Commonly input at 1.0 eq per aryl functionalization step, adjustable (0.85–1.15 eq) based on synthetic route efficiency and impurity specification.

Downstream process integration

• Introduced as a core coupling reagent in combinatorial chemistry for CNS ligand libraries; removed Boc group and further derivatized in final API isolation and crystallization steps. Stringent process analytics verify trace piperazine and benzoic acid derivatives throughout.

Final product types

• Psychoactive pharmaceutical intermediates (antipsychotics and antidepressants)
• CNS-active experimental drug candidates
• Analytical reference substances for bioequivalence studies
• Formulation lots for clinical trial supply

4. Advanced R&D for Structure-Activity Relationship (SAR) Libraries

Pharmaceutical research organizations and large discovery teams integrate the compound in high-throughput synthesis of SAR libraries centered on piperazine-linked benzoic acid motifs. The Boc group ensures orthogonal protection for diverse molecular derivatization, vital for rapid analog generation and screening. This application relies on predictable reactivity and high-purity supply for automation platforms, where trace-level contaminant management ensures reproducible SAR outcomes in medicinal chemistry and lead optimization pipelines.

Industry compliance standards

• ISO 17034:2016 for reference material producers (for analytical validation of standards)
• Guidance for Industry: Analytical Procedures and Methods Validation for Drugs (US FDA, EMA/CHMP)
• GLP (Good Laboratory Practice) for R&D compound handling
• Internal QA/QC systems for SAR and discovery libraries

Typical usage ratio

• Input per reaction scale ranges from micromolar to sub-molar, adapted to automated parallel synthesis protocols. Typical concentrations: 10–50 mmol for microplate libraries; scale-ups adjusted for hit-to-lead expansion phases.

Downstream process integration

• Dosed as a protected piperazine-benzoic acid scaffold for rapid coupling/diversification; deprotection strategies depend on library design and downstream bioassay timing. Used throughout combinatorial chemistry flows and subject to automated purification and structure confirmation steps.

Final product types

• SAR compound libraries for target screening
• Lead compound pools for medicinal chemistry optimization
• Standardized reference compounds for method development
• Custom reagents for preclinical target engagement assays